Autolus Therapeutics (AUTL) Stock Forecast & Price Target

Autolus Therapeutics is viewed favorably because its lead CAR-T therapy, obe-cel, is showing a compelling balance of efficacy and safety, with Phase 1 CARLYSLE data showing a 50% complete renal response in 3/6 patients at a median 11.4 months follow-up and 0% Grade 3+ CRS or ICANS, while the pivotal single-arm Phase 2 LUMINA trial enrolls 30 refractory lupus nephritis patients who have already failed more than 2 immunosuppressive therapies. The outlook is further strengthened by commercialization momentum, as Aucatzyl generated $26.2M in 1Q26 revenue, management reiterated 2026 revenue guidance of $120-135M, and the number of authorized treatment centers rose from 67 to 73 with growth to more than 80 still expected by YE2026. Additional upside comes from multiple de-risking and expansion catalysts, including long-term CARLYSLE follow-up expected at ACR Convergence in late 2026, LUMINA data guided to 2028, frontline consolidation evidence that could support NCCN guideline changes in 2027, and pediatric first-relapse expansion through the planned CATULUS study enlargement.

Autolus Therapeutics is weighed down by a still-unproven commercial and clinical profile: even after achieving its first quarter of gross margin profit, 1Q26 COGS remained 94% of sales, operating expenses were $85.7M, the operating loss was $59.5M, and EPS was ($0.27), underscoring that the business remains deeply loss-making and highly dependent on future execution. Its lead asset, Aucatzyl/obe-cel, still faces meaningful scientific and regulatory risk because CAR-T administration and manufacturing are complex, known toxicities such as CRS, neurotoxicity, and severe cytopenias can limit adoption, most patients eventually progress, and the company is competing against entrenched CD19 CAR products from Novartis and Gilead in indications where incumbent therapy is already established. Although management is reducing the workforce by 13% and expects ~$15M in annualized savings starting in 2027, the cash balance of $229.4M is only expected to fund operations into 2H27, so the negative outlook is driven by ongoing cash burn, competitive pressure, and reliance on later clinical readouts from 2026 and 2027 to justify broader uptake.